IL246545B - History of 3-hydroxy-3-[(cyclopropylmethoxy)-4-(fluoro)phenyl]-4-(h1- 3,2,1-triazol-1-yl)-butane and pharmaceutical preparations containing them - Google Patents

History of 3-hydroxy-3-[(cyclopropylmethoxy)-4-(fluoro)phenyl]-4-(h1- 3,2,1-triazol-1-yl)-butane and pharmaceutical preparations containing them

Info

Publication number
IL246545B
IL246545B IL246545A IL24654516A IL246545B IL 246545 B IL246545 B IL 246545B IL 246545 A IL246545 A IL 246545A IL 24654516 A IL24654516 A IL 24654516A IL 246545 B IL246545 B IL 246545B
Authority
IL
Israel
Prior art keywords
cyclopropylmethoxy
triazol
fluoro
hydroxy
phenyl
Prior art date
Application number
IL246545A
Other languages
English (en)
Hebrew (he)
Other versions
IL246545A0 (en
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of IL246545A0 publication Critical patent/IL246545A0/en
Publication of IL246545B publication Critical patent/IL246545B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL246545A 2014-01-03 2016-06-30 History of 3-hydroxy-3-[(cyclopropylmethoxy)-4-(fluoro)phenyl]-4-(h1- 3,2,1-triazol-1-yl)-butane and pharmaceutical preparations containing them IL246545B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461923534P 2014-01-03 2014-01-03
PCT/US2015/010059 WO2015103489A1 (en) 2014-01-03 2015-01-02 Heteroatom containing deoxyuridine triphosphatase inhibitors

Publications (2)

Publication Number Publication Date
IL246545A0 IL246545A0 (en) 2016-08-31
IL246545B true IL246545B (en) 2020-05-31

Family

ID=53494059

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246545A IL246545B (en) 2014-01-03 2016-06-30 History of 3-hydroxy-3-[(cyclopropylmethoxy)-4-(fluoro)phenyl]-4-(h1- 3,2,1-triazol-1-yl)-butane and pharmaceutical preparations containing them

Country Status (7)

Country Link
US (2) US9790214B2 (2)
EP (1) EP3089964B1 (2)
JP (1) JP6513095B2 (2)
CN (1) CN106061952B (2)
CA (1) CA2935717C (2)
IL (1) IL246545B (2)
WO (1) WO2015103489A1 (2)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914178C (en) 2013-01-07 2023-06-13 University Of Southern California Deoxyuridine triphosphatase inhibitors
JP6513095B2 (ja) 2014-01-03 2019-05-15 ユニバーシティ オブ サザン カリフォルニア ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
WO2017006271A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
PT3319939T (pt) 2015-07-08 2025-03-05 Cv6 Therapeutics Ni Ltd Inibidores de desoxiuridina-trifosfatase contendo hidantoína
US11168059B2 (en) 2016-11-23 2021-11-09 Cv6 Therapeutics (Ni) Limited Amino sulfonyl compounds
US10829457B2 (en) 2016-11-23 2020-11-10 Cv6 Therapeutics (Ni) Limited Nitrogen ring linked deoxyuridine triphosphatase inhibitors
WO2018098204A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited 6-membered uracil isosteres
US11014924B2 (en) 2016-11-23 2021-05-25 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
US10858344B2 (en) 2016-11-23 2020-12-08 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018128720A1 (en) 2017-01-05 2018-07-12 Cv6 Therapeutics (Ni) Limited Uracil containing compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787766A (fr) 1971-08-21 1973-02-19 Merck Patent Gmbh Imides d'acide glutarique et leur procede de preparation
US4304715A (en) 1979-06-08 1981-12-08 Derek Hudson Enkephalin analogues
JPS5839672A (ja) 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd ウラシル誘導体
JPH0674251B2 (ja) * 1986-02-07 1994-09-21 全薬工業株式▲会▼社 ビス−ジオキソピペラジン誘導体
JPS63101361A (ja) 1986-09-08 1988-05-06 ブリティッシュ・テクノロジー・グループ・リミテッド ジオキソピペリジン誘導体を含有する不安解消組成物
FR2644786B1 (fr) * 1989-03-21 1993-12-31 Adir Cie Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5599796A (en) 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
US5962246A (en) 1996-03-29 1999-10-05 The University Of Medicine And Dentistry Of New Jersey dUTPase, its isoforms, and diagnostic and other uses
JPH09286786A (ja) 1996-04-18 1997-11-04 Nippon Paper Ind Co Ltd ピリミジン誘導体及びその抗腫瘍剤としての用途
WO1999031066A1 (en) 1997-12-18 1999-06-24 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridones as src family sh2 domain inhibitors
EP1165500A1 (en) 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
DE10002509A1 (de) 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
JP2002284686A (ja) 2001-03-28 2002-10-03 Sankyo Co Ltd スルホンアミド化合物を含有する医薬組成物
JP2004527535A (ja) * 2001-04-11 2004-09-09 クイーンズ ユニバーシティ アット キングストン 抗発作発生剤および/または抗癲癇誘発剤としてのピリミジン化合物
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
GB0400290D0 (en) 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
EP1848433A2 (en) 2005-01-25 2007-10-31 Celgene Corporation Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
WO2006135763A2 (en) 2005-06-09 2006-12-21 The Johns Hopkins University Inhibitors of dna repair enzymes and methods of use thereof
KR20110089463A (ko) 2006-07-24 2011-08-08 한국화학연구원 신규 hiv 역전사 효소 억제제
EP1939186A1 (en) 2006-12-22 2008-07-02 Sulfidris S.r.l. 5-Fluorouracil derivatives and their use for the treatment of cancer
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
US8530490B2 (en) * 2008-06-03 2013-09-10 Taiho Pharmaceutical Co., Ltd. Uracil compound or salt thereof having human deoxyuridine triphosphatase inhibitory activity
US20110212467A1 (en) 2008-08-27 2011-09-01 University Of Southern California INHIBITORS OF dUTPase
JP2011231015A (ja) * 2008-08-29 2011-11-17 Taiho Yakuhin Kogyo Kk 含窒素複素環を有する新規ウラシル化合物又はその塩
ES2401965T3 (es) 2009-02-19 2013-04-25 Novo Nordisk A/S Modificación de Factor VIII
CN103948599B (zh) * 2009-11-30 2016-03-09 大鹏药品工业株式会社 抗肿瘤效果增强剂
JP2013032293A (ja) 2009-11-30 2013-02-14 Taiho Yakuhin Kogyo Kk ヒトdUTPase阻害活性を有する5−フルオロウラシル化合物又はその塩
JP2013047189A (ja) 2009-12-25 2013-03-07 Kyorin Pharmaceutical Co Ltd 新規パラバン酸誘導体及びそれらを有効成分とする医薬
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
EP2508158B1 (en) 2011-04-04 2014-07-02 Arjo Hospital Equipment AB Hoist apparatus
CA2914178C (en) * 2013-01-07 2023-06-13 University Of Southern California Deoxyuridine triphosphatase inhibitors
JP6513095B2 (ja) 2014-01-03 2019-05-15 ユニバーシティ オブ サザン カリフォルニア ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤
US20180110780A1 (en) 2015-04-30 2018-04-26 Taiho Pharmaceutical Co., Ltd. Agent for alleviating side effect of antitumor drug
AU2016258388B2 (en) 2015-05-01 2019-03-28 Taiho Pharmaceutical Co., Ltd. Novel crystal of uracil compound
US10544105B2 (en) 2015-07-08 2020-01-28 Cv6 Therapeutics (Ni) Limited Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage
WO2017006271A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage
WO2017006270A1 (en) 2015-07-08 2017-01-12 University Of Southern California Deoxyuridine triphosphatase inhibitors
PT3319939T (pt) 2015-07-08 2025-03-05 Cv6 Therapeutics Ni Ltd Inibidores de desoxiuridina-trifosfatase contendo hidantoína

Also Published As

Publication number Publication date
US20180086746A1 (en) 2018-03-29
CA2935717A1 (en) 2015-07-09
US20160326149A1 (en) 2016-11-10
CN106061952A (zh) 2016-10-26
WO2015103489A1 (en) 2015-07-09
EP3089964A1 (en) 2016-11-09
EP3089964A4 (en) 2018-01-17
IL246545A0 (en) 2016-08-31
JP2017502967A (ja) 2017-01-26
CN106061952B (zh) 2022-01-28
JP6513095B2 (ja) 2019-05-15
US9790214B2 (en) 2017-10-17
EP3089964B1 (en) 2021-02-24
US10457673B2 (en) 2019-10-29
CA2935717C (en) 2022-06-21

Similar Documents

Publication Publication Date Title
IL246545B (en) History of 3-hydroxy-3-[(cyclopropylmethoxy)-4-(fluoro)phenyl]-4-(h1- 3,2,1-triazol-1-yl)-butane and pharmaceutical preparations containing them
IL247836A0 (en) 1, 3-benzodioxole derivatives, preparations containing them and their uses
IL247062A0 (en) Heterocyclic compounds, their preparation and pharmaceutical preparations containing them
IL259044B (en) compounds for oral care
IL253538A0 (en) Heterocyclic compound and pharmaceutical compound containing it
IL253705A0 (en) Converted triazoles, preparations containing them and their uses
ZA201705124B (en) Fungicidal compounds and compositions
ZA201804448B (en) Composition for crop care and protection
EP3397252A4 (en) COMPOSITIONS OF PERSONAL CARE
IL248773B (en) History -6,1-Naphthyridine-5,4-Dione and pharmaceutical preparations containing them
IL252897A0 (en) Indanyl compounds, pharmaceutical preparations and their medical uses
PL3320903T3 (pl) Kompozycja farmaceutyczna zawierająca amlodypinę, walsartan i rosuwastatynę
ZA201803909B (en) Oral care compositions
IL260085B (en) Preparations containing a phenylaminopyrimidine derivative
ZA201706785B (en) Oral care compositions
IL252683A0 (en) Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses
ES3064415T3 (en) Hygiene fragrance compositions
IL248256B (en) Cyclohexenyl compounds, compositions comprising them and uses thereof
IL252744A0 (en) Solid forms comprising (1E,4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[bi]azepine-4-carboxamide, their preparations and their uses
PL3355862T3 (pl) Doustne kompozycje przeciwdrobnoustrojowe na bazie krzemionki
LT3389638T (lt) Farmacinė kompozicija, kurios sudėtyje yra pimobendano
SG11201708597VA (en) Oral care composition
IL256589B (en) 7,4,2-trimethyloct-6-en-1-ol as a fragrance component
IL258305A (en) compounds for oral care
ZA201800096B (en) Oral care compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed